-       Report 
   - October 2025
    -  22 Pages 
    Uzbekistan
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  26 Pages 
    Taiwan
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - September 2025
    -  26 Pages 
    Canada
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - September 2025
    -  27 Pages 
    South Korea
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - September 2025
    -  27 Pages 
    Mexico
   
   From       €995EUR$1,186USD£903GBP 
                 -       Report 
   - September 2025
    -  25 Pages 
    Colombia
   
   From       €995EUR$1,186USD£903GBP 
                From       €995EUR$1,186USD£903GBP 
                -       Report 
   - September 2025
    -  31 Pages 
    Australia
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - September 2025
    -  22 Pages 
    Azerbaijan
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - January 2025
    -  25 Pages 
    India
   
   From       €995EUR$1,186USD£903GBP 
                -       Report 
   - May 2022
    -  109 Pages 
    South Africa
   
   From       €2562EUR$2,850USD£2,247GBP 
                  -       Report 
   - October 2025
    -  23 Pages 
    Ireland
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  25 Pages 
    Spain
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  25 Pages 
    Italy
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  26 Pages 
    South Africa
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  22 Pages 
    North Macedonia
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  26 Pages 
    Thailand
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  24 Pages 
    Saudi Arabia
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  25 Pages 
    France
   
   From       €995EUR$1,186USD£903GBP 
                  -       Report 
   - October 2025
    -  23 Pages 
    Indonesia
   
   From       €995EUR$1,186USD£903GBP 
             
         The Decongestant market is a subset of the Cough and Cold Drugs market, which includes medications used to treat symptoms of the common cold, such as nasal congestion, sinus pressure, and chest congestion. Decongestants are typically available in both over-the-counter (OTC) and prescription forms, and are often used in combination with other medications to treat cold and flu symptoms. Decongestants work by narrowing the blood vessels in the nasal passages, reducing inflammation and allowing for    easier breathing.
Common OTC decongestants include pseudoephedrine, phenylephrine, and oxymetazoline. Prescription decongestants include ephedrine, phenylephrine, and phenylpropanolamine. Decongestants are also available in combination with other medications, such as antihistamines, expectorants, and cough suppressants.
Some companies in the Decongestant market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Merck, and Sanofi. Show Less   Read more